Irena Seili-Bekafigo

Dr. Irena Seili-Bekafigo

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2010 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
SŠSanja Štifter
Sanja Štifter
EBEmina Babarovic
Emina Babarovic
TVToni Valković
Toni Valković
ISIrena Seili-Bekafigo
Irena Seili-Bekafigo
CŠChristophe Štemberger
Christophe Štemberger
NJNives Jonjić
Nives Jonjić
Background: Estimation of plasma cell infiltrates in bone marrow aspirates (BMA) and bone marrow biopsy (BMB) is a standard method in the diagnosis and monitoring of multiple myeloma (MM). Plasma cell fraction in the bone marrow is therefore critical for the classification and optimal clinical management of patients with plasma cell dyscrasias. The aim of the study was to compare the percentage of plasma cells obtained by both methods with the patient clinical parameters and survival. Methods: This retrospective study included BMA and BMB of 59 MM patients. The conventional differential count was determined in BMA to estimate the percentage and cytologic grade of plasma cells. The pattern of neoplastic infiltration and percentage of plasma cells were estimated on CD138 immunostained BMB slides microscopically and by computer-assisted image analysis (CIA). Results: Significantly higher values of plasma cell infiltrates were observed in pathologist (47.7 ± 24.8) and CIA (44.1 ± 30.6) reports in comparison with cytologist analysis (30.6 ± 17.1; P < 0.001 and P < 0.0048, respectively). BMB assessment by pathologist counting and using CIA showed strongest correlation (r = 0.8; P < 0.0001). Correlation was also observed between the pathologist and cytologist counts (r = 0.321; P = 0.015) as well as comparing the percentage of plasma cells in BMA and CIA (r = 0.27; P = 0.05). Patients with clinical stage I/II had a significantly lower CIA plasma cell count than those with clinical stage III (P = 0.008). Overall survival was shorter in patients with more than 25% of atypical plasma cell morphology estimated in BMA (P = 0.05) and a higher percentage of tumor cell infiltrates estimated by the pathologist and CIA (P = 0.0341 and P = 0.013, respectively). Conclusion: Study results suggested the combined analyses to be useful as a routine procedure to achieve more accurate and informative diagnostic data.

1 June 2012 in American Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
EBEmina Babarovic
Emina Babarovic
TVToni Valković
Toni Valković
SŠSanja Štifter
Sanja Štifter
IBIvana Budisavljević
Ivana Budisavljević
ISIrena Seili-Bekafigo
Irena Seili-Bekafigo
NJNives Jonjić
Nives Jonjić
The aim of our study was to emphasize the importance of accurate and standardized techniques for detailed monitoring of the microenvironment in multi

1 January 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
TVToni Valković
Toni Valković
EBEmina Babarovic
Emina Babarovic
KLKsenija Lučin
Ksenija Lučin
SŠSanja Štifter
Sanja Štifter
MAMerica Aralica
Merica Aralica
NJNives Jonjić
Nives Jonjić
The aim of this pilot study was to determine the plasma levels of osteopontin (OPN) and vascular endothelial growth factor (VEGF) and find possible association between them and main clinical features and parameters of tumor burden in patient with multiple myeloma (MM). Plasma levels of OPN and VEGF were determined in 44 newly diagnosed MM patients and 24 healthy persons by ELISA method. These values were compared with the presence of anemia, renal dysfunction, and bone lesions as myeloma related clinical manifestations and with serum beta-2 microglobulin and Durie-Salmon clinical stage as prognosticators related to tumor mass. The value of OPN was significantly higher in MM patients with evident bone lesions (P=0.03) and there was also a positive correlation with serum beta-2 microglobulin (r=0.366;P=0.04). Furthermore, patients with lower Durie-Salmon stage had significantly lower OPN and VEGF levels (P=0.05;P=0.04, resp.). Our preliminary results found positive association between plasma level of OPN, tumor burden, and bone destruction. Further analysis should provide information about the possible use of OPN as useful clinical biomarker for monitoring bone disease and tumor mass, as well as a prognostic factor, or a possible target for pharmacological intervention.

1 January 2016 in BioMed Research International
Verified
Journal Article
Open access
PDF file
TVToni Valković
Toni Valković
EBEmina Babarović
Emina Babarović
KLKsenija Lučin
Ksenija Lučin
SŠSanja Štifter
Sanja Štifter
MAMerica Aralica
Merica Aralica
NJNives Jonjić
Nives Jonjić
The aim of this pilot study was to determine the plasma levels of monocyte chemotactic protein-1 (MCP-1) and possible associations with angiogenesis and the main clinical features of untreated patients with multiple myeloma (MM). ELISA was used to determine plasma MCP-1 levels in 45 newly diagnosed MM patients and 24 healthy controls. The blood vessels were highlighted by immunohistochemical staining, and computer-assisted image analysis was used for more objective and accurate determination of two parameters of angiogenesis: microvessel density (MVD) and total vascular area (TVA). The plasma levels of MCP-1 were compared to these parameters and the presence of anemia, renal dysfunction, and bone lesions. A significant positive correlation was found between plasma MCP-1 concentrations and TVA (p=0.02). The MCP-1 levels were significantly higher in MM patients with evident bone lesions (p=0.01), renal dysfunction (p=0.02), or anemia (p=0.04). Therefore, our preliminary results found a positive association between plasma MCP-1 levels, angiogenesis (expressed as TVA), and clinical features in patients with MM. However, additional prospective studies with a respectable number of patients should be performed to authenticate these results and establish MCP-1 as a possible target of active treatment.

30 April 2012 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
PDF file
KMKoraljka Rajković Molek
Koraljka Rajković Molek
ISIrena Seili-Bekafigo
Irena Seili-Bekafigo
CŠChristophe Štemberger
Christophe Štemberger
NJNives Jonjić
Nives Jonjić
GĐGordana Đordević
Gordana Đordević
ADAntica Duletić‐Načinović
Antica Duletić‐Načinović

8 March 2006 in Journal of Travel Medicine
Verified
Journal Article
Open access
PDF file
MMMiro Morovic
Miro Morovic
IPIvica Poljak
Ivica Poljak
BMBojan Miletic
Bojan Miletic
BTBiserka Troselj-Vukic
Biserka Troselj-Vukic
ISIrena Seili-Bekafigo
Irena Seili-Bekafigo
IMIrena Milotic
Irena Milotic
Miro Morovic, Ivica Poljak, Bojan Miletic, Biserka Troselj-Vukic, Irene Seili-Bekafigo, Irena Milotic; Late Symptomatic Plasmodium malariae Relapse in the Terr